Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Tyler W. Buckner, Craig Kessler, Giancarlo Castaman, Cédric Hermans, Victor Jimenez-Yuste, Johnny Mahlangu, Wolfgang A. Miesbach, Johannes Oldenburg, Michael Recht, Leonard A. Valentino, Allison P Wheeler, Steven W. Pipe

Blood (2024) 144 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2024-194935

Published: 2024

Journal Articles

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Carolyn M Millar, Priyanka Raheja, Allison P Wheeler, Shrinath Kshirsagar, Christian Schoergenhofer, Nicoletta C Machin, Cihan Ay, Almudena Tercero, Hayley Lane, Christopher J Horvath, Sandip Panicker, Gary Patou, Benjamin Kim, Savita Rangarajan

Blood (2024) 144 (Supplement 1): 3981.

https://doi.org/10.1182/blood-2024-208020

Published: 2024

Journal Articles

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Allison P. Wheeler, Aby Abraham, Chris Barnes, Renée Brown Frandsen, Kingsley Hampton, Francisco José López Jaime, Camila Martins Mazini Tavares, Keiji Nogami, Jerzy Windyga, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2024-209752

Published: 2024

Journal Articles

Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Janice Staber, Alix Arnaud, Ion Agirrezabal, Lane Anson, Andrew Wilson, Nana Kragh, Doris V. Quon, Allison P Wheeler

Blood (2024) 144 (Supplement 1): 2582.

https://doi.org/10.1182/blood-2024-207568

Published: 2024

Journal Articles

Combatt HMB-Recon: Combination Therapy in Adolescents to Treat Heavy Menstrual Bleeding-Review of Charts to Observe Treatment Patterns

Lauren E. Amos, Hung-Wen Yeh, Ayesha Zia, Meera Chitlur, Lynn Malec, Allison P. Wheeler

Blood (2024) 144 (Supplement 1): 556.

https://doi.org/10.1182/blood-2024-210969

Published: 2024

Journal Articles

Title: Real-World Utilization of Human Fibrinogen Concentrate in Managing Bleeding in Adult and Pediatric Patients: A Retrospective Study

Jonathan Tucci, Allison P Wheeler

Blood (2024) 144 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2024-206568

Published: 2024

Journal Articles

Treatment-Related Clinical and Humanistic Unmet Needs in Hemophilia A without Inhibitors

Allison P Wheeler, John Waller, Sanket Shah, Mohd Nawi bin Wahid, Jennifer Dusendang, Amy D. Shapiro

Blood (2023) 142 (Supplement 1): 508.

https://doi.org/10.1182/blood-2023-179128

Published: 2023

Journal Articles

Real-World Unmet Needs in Patients with Hemophilia A without Inhibitors in the US: Results from the PicnicHealth Database

Courtney Thornburg, Allison P Wheeler, Sylvie Bozzi, Gandarvaka Miles, Kalyani Hawaldar, Andrew Wilson, Gillian Hanson, Noelle Liao, Amanda Wilson

Blood (2023) 142 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2023-181655

Published: 2023

Journal Articles

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Blood (2022) 140 (Supplement 1): 1413–1415.

https://doi.org/10.1182/blood-2022-156921

Published: 2022

Journal Articles

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Allison P. Wheeler, Gary Benson, Hermann Eichler, Sidsel Marie Tønder, Katarina Cepo, Victor Jimenez Yuste, Kaan Kavakli, Lily LL Wong, Tadashi Matsushita

Blood (2021) 138 (Supplement 1): 345.

https://doi.org/10.1182/blood-2021-148571

Published: 2021

Journal Articles

Longitudinal Efficacy and Safety of N8-GP for Prophylaxis and Bleed Control in US Patients

Allison P. Wheeler, Miguel A. Escobar, Susan Kearney, Janice M. Staber, Adam R. Wufsus, Vlady Ostrow, Steven R. Lentz

Blood (2021) 138 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2021-147814

Published: 2021

Journal Articles

Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study

Allison P. Wheeler, Edward L. Snyder, Majed A. Refaai, Claudia S. Cohn, Jessica Poisson, Magali J. Fontaine, Mary Sehl, Ajay K. Nooka, Lynne Uhl, Philip C. Spinella, Maly Fenelus, Darla Liles, Thomas Coyle, Joanne Becker, Michael R. Jeng, Kathy Liu, Richard J Benjamin, Laurence Corash

Blood (2021) 138 (Supplement 1): 1077.

https://doi.org/10.1182/blood-2021-146916

Published: 2021

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Genotype Analysis of Adolescents with Heavy Menstrual Bleeding and Low Von Willebrand Activity - Report of a Multi-Center Study

Brooke Sadler, PhD, Charles Minard, PhD, Gabe Haller, Christina Gurnett, Sarah H. O'Brien, MD, Allison P. Wheeler, MD, Eric S. Mullins, MD, Mukta Sharma, MD MPH, Robert F. Sidonio, Jr., MD MSc., Shilpa Jain, Ayesha Zia, MD, Margaret V. Ragni, MDMPH, Roshni Kulkarni, MD, Jennifer Dietrich, Peter A. Kouides, MD, Jorge Di Paola, Lakshmi Srivaths, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-135886

Published: 2020

Journal Articles

Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136814

Published: 2020

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Blood (2019) 134 (Supplement_1): 1130.

https://doi.org/10.1182/blood-2019-124234

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Resolution, and Perioperative Management

Miguel A. Escobar, MD, Allison P. Wheeler, MD, Steven R. Lentz, MD PhD, Wan Hui Ong Clausen, PhD, David Cooper

Blood (2019) 134 (Supplement_1): 3635.

https://doi.org/10.1182/blood-2019-124889

Published: 2019

Journal Articles

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study

Blood (2018) 132 (Supplement 1): 2479.

https://doi.org/10.1182/blood-2018-99-119637

Published: 2018

NARROW

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Combatt HMB-Recon: Combination Therapy in Adolescents to Treat Heavy Menstrual Bleeding-Review of Charts to Observe Treatment Patterns

Title: Real-World Utilization of Human Fibrinogen Concentrate in Managing Bleeding in Adult and Pediatric Patients: A Retrospective Study

Treatment-Related Clinical and Humanistic Unmet Needs in Hemophilia A without Inhibitors

Real-World Unmet Needs in Patients with Hemophilia A without Inhibitors in the US: Results from the PicnicHealth Database

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Longitudinal Efficacy and Safety of N8-GP for Prophylaxis and Bleed Control in US Patients

Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Genotype Analysis of Adolescents with Heavy Menstrual Bleeding and Low Von Willebrand Activity - Report of a Multi-Center Study

Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Resolution, and Perioperative Management

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only